Genetic Testing Decision Aid

Status Recruiting

Clinical Trial Summary

This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer

Clinical Trial Description

The research study procedures include: screening for eligibility and study questionnaires that would be performed in conjunction with either the genetic counselor visit or use of the electronic decision aid. The study questionnaires include: - Knowledge Survey - Shared Decision Making Process Survey - Decisional Conflict Scale The research study will last up to 2 weeks. It is expected that about 350 people will take part in this research study. The National Cancer Institute (NCI) is supporting this research study by providing funding for the research ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05470920
Study type	Interventional
Source	Massachusetts General Hospital
Contact	Daniel C. Chung, MD
Phone	(617) 726-8687
Email	Chung.daniel@mgh.harvard.edu
Status	Recruiting
Phase	N/A
Start date	October 14, 2022
Completion date	October 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06065891` - Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer	N/A
Recruiting	`NCT05351983` - Patient-derived Organoids Drug Screen in Pancreatic Cancer	N/A
Completed	`NCT01774162` - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration	N/A
Recruiting	`NCT04164602` - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Recruiting	`NCT05325281` - CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma	Phase 1
Completed	`NCT05161013` - A Proof-of-Concept Study Evaluating LINFU™	N/A
Recruiting	`NCT04099134` - PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
Recruiting	`NCT05518071` - FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1	Phase 2
Withdrawn	`NCT04045730` - The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.	Phase 2
Recruiting	`NCT06160596` - Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Recruiting	`NCT04636788` - Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer	N/A
Recruiting	`NCT04435067` - Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)
Recruiting	`NCT04571294` - Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy	N/A
Active, not recruiting	`NCT03472716` - The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)
Completed	`NCT03532347` - Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study)	N/A
Withdrawn	`NCT06090318` - Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss	Phase 1/Phase 2
Not yet recruiting	`NCT06381882` - The Role of the Human Microbiome in Patients After Pancreatic Resection.
Recruiting	`NCT03544255` - Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues
Recruiting	`NCT05340569` - Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.	N/A
Active, not recruiting	`NCT04241367` - Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy